Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
77M
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
14.3M
-
Shares change
-
+1.51M
-
Total reported value, excl. options
-
$39.1M
-
Value change
-
+$4.32M
-
Number of buys
-
15
-
Number of sells
-
-15
-
Price
-
$2.74
Significant Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) as of Q4 2020
47 filings reported holding CLSD - Clearside Biomedical, Inc. - Common Stock, $0.001 par value as of Q4 2020.
Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.3M shares
of 77M outstanding shares and own 18.52% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.96M shares), Carmignac Gestion (3.54M shares), VANGUARD GROUP INC (1.69M shares), Acuta Capital Partners, LLC (1.25M shares), AJU IB Investment Co., Ltd. (794K shares), BlackRock Inc. (765K shares), RENAISSANCE TECHNOLOGIES LLC (459K shares), GEODE CAPITAL MANAGEMENT, LLC (326K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (184K shares), and FIRST MANHATTAN CO (175K shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.